These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 10537952)

  • 1. The clinical and economic potential of cyclosporin drug interactions.
    Martin JE; Daoud AJ; Schroeder TJ; First MR
    Pharmacoeconomics; 1999 Apr; 15(4):317-37. PubMed ID: 10537952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of other drugs to allow a lower dosage of cyclosporin to be used. Therapeutic and pharmacoeconomic considerations.
    Jones TE
    Clin Pharmacokinet; 1997 May; 32(5):357-67. PubMed ID: 9160170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survey of cyclosporin-sparing agent use in Australasian transplant centres.
    Jones TE
    Aust N Z J Med; 1996 Dec; 26(6):772-6. PubMed ID: 9028506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporin microemulsion (Neoral). A pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation.
    Coukell AJ; Plosker GL
    Pharmacoeconomics; 1998 Dec; 14(6):691-708. PubMed ID: 10346420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically significant drug interactions with cyclosporin. An update.
    Campana C; Regazzi MB; Buggia I; Molinaro M
    Clin Pharmacokinet; 1996 Feb; 30(2):141-79. PubMed ID: 8906896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes.
    Orme ME; Jurewicz WA; Kumar N; McKechnie TL
    Pharmacoeconomics; 2003; 21(17):1263-76. PubMed ID: 14986738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diltiazem co-treatment in renal transplant patients receiving microemulsion cyclosporin.
    Kumana CR; Tong MK; Li CS; Lauder IJ; Lee JS; Kou M; Walley T; Haycox A; Chan TM
    Br J Clin Pharmacol; 2003 Dec; 56(6):670-8. PubMed ID: 14616428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.
    Dunn CJ; Wagstaff AJ; Perry CM; Plosker GL; Goa KL
    Drugs; 2001; 61(13):1957-2016. PubMed ID: 11708766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus versus cyclosporin in renal transplantation in Italy: cost-minimisation and cost-effectiveness analyses.
    Lazzaro C; McKechnie T; McKenna M
    J Nephrol; 2002; 15(5):580-8. PubMed ID: 12455727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions of cyclosporin A and amlodipine: blood cyclosporin A levels, hypertension and kidney function.
    Schrama YC; Koomans HA
    J Hypertens Suppl; 1998 Sep; 16(4):S33-8. PubMed ID: 9817190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nicardipine as antihypertensive therapy in liver transplant recipients: results of long-term use.
    Duvoux C; Cherqui D; Di Martino V; Métreau JM; Salvat A; Lauzet JY; Fagniez PL; Dhumeaux D
    Hepatology; 1997 Feb; 25(2):430-3. PubMed ID: 9021959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporin: a pharmacoeconomic evaluation of its use in renal transplantation.
    Frampton JE; Faulds D
    Pharmacoeconomics; 1993 Nov; 4(5):366-95. PubMed ID: 10146875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diltiazem does not always increase blood cyclosporin concentration.
    Jones TE; Morris RG
    Br J Clin Pharmacol; 1996 Nov; 42(5):642-4. PubMed ID: 8951199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppressive drugs in paediatric liver transplantation.
    van Mourik ID; Kelly DA
    Paediatr Drugs; 2001; 3(1):43-60. PubMed ID: 11220404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcineurin inhibitors in renal transplantation: what is the best option?
    Tanabe K
    Drugs; 2003; 63(15):1535-48. PubMed ID: 12887261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach.
    McLachlan AJ; Tett SE
    Ther Drug Monit; 1998 Aug; 20(4):390-5. PubMed ID: 9712463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporin and ketoconazole, drug interaction or therapeutic association?
    Albengres E; Tillement JP
    Int J Clin Pharmacol Ther Toxicol; 1992 Dec; 30(12):555-70. PubMed ID: 1473871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic optimisation of oral antifungal therapy.
    Schäfer-Korting M
    Clin Pharmacokinet; 1993 Oct; 25(4):329-41. PubMed ID: 8261715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coadministration of ketoconazole and cyclosporine for kidney transplant recipients: long-term follow-up and study of metabolic consequences.
    Sobh MA; Hamdy AF; El Agroudy AE; El Sayed K; El-Diasty T; Bakr MA; Ghoneim MA
    Am J Kidney Dis; 2001 Mar; 37(3):510-7. PubMed ID: 11228175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.